Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis
Background Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therap...
সংরক্ষণ করুন:
| প্রধান লেখক: | , , , , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Taylor & Francis Group
2026-12-01
|
| মালা: | Annals of Medicine |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.tandfonline.com/doi/10.1080/07853890.2026.2634532 |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|